Study Title: A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Praneeth Baratam, at baratamp@musc.edu.Study Coordinator, Hana Baker, at bakerhan@musc.edu.Trial opened at the following institutions: Medical University of South Carolina